Circular RNA hsa_circ_0003288 induces EMT and invasion by regulating hsa_circ_0003288/miR-145/PD-L1 axis in hepatocellular carcinoma

Guili Xu1†, Peng Zhang1†, Hansi Liang2, Yunhua Xu1, Jian Shen1, Wansheng Wang1, Mingming Li1, Jintao Huang1, Caifang Ni1*, Xueguang Zhang2* and Xiaoli Zhu1*

Abstract

Background: Epithelial-mesenchymal transition (EMT) has been associated with wound healing, tumorigenesis, and metastasis. Circular RNAs (circRNAs) are functional non-coding RNAs involved in multiple human cancers. However, whether and how circRNAs contribute to the EMT in hepatocellular carcinomas (HCC) remains to be deciphered. In this study, we investigated the regulation and function of hsa_circ_0003288 on programmed death-1 ligand 1 (PD-L1) during EMT and HCC invasiveness.

Methods: Hsa_circ_0003288 expression was measured by real-time quantitative reverse transcriptase PCR (qRT-PCR). Luciferase reporter assays, RNA pull-down assay and fluorescence in situ hybridization (FISH) were used to determine the correlation between hsa_circ_0003288 and miR-145 and between miR-145 and PD-L1. Furthermore, ectopic over-expression and siRNA-mediated downregulation of hsa_circ_0003288, transwell assays, and in vivo studies were used to determine the function of hsa_circ_0003288 on the EMT and invasiveness of L02 and HCC cells.

Results: miR-145 directly targeted the PD-L1 3′-untranslated region (UTR) region, and hsa_circ_0003288 acted as a miR-145 sponge to regulate PD-L1 expression. Overexpression of hsa_circ_0003288 increased PD-L1 levels and promoted EMT, migration, and invasiveness of L02 cells. These observations were reversed after knockdown of hsa_circ_0003288 in HepG2 and Huh7 cells. Overexpression of PD-L1 rescued EMT, migration, and invasiveness of HepG2 and Huh7 cells after knockdown of hsa_circ_0003288. Furthermore, hsa_circ_0003288 knocked down EMT in vivo studies. Hsa_circ_0003288/PD-L1 axis was found to mediate the metastatic phenotypes via the PI3K/Akt pathway in HCC. Additionally, expression levels of hsa_circ_0003288 were increased and positively correlated with PD-L1 expression in HCC tissues.

Conclusion: Our findings demonstrated that hsa_circ_0003288 promoted EMT and invasion of HCC via the hsa_circ_0003288/miR-145/PD-L1 axis through the PI3K/Akt pathway. Targeting hsa_circ_0003288 may be a therapeutic strategy for the treatment of HCC.

Keywords: Hepatocellular carcinoma, Hsa, Circ, 0,003,288, MiR-145, PD-L1, EMT
and metastasis [2]. Understanding the possible molecular mechanisms underlying EMT in HCC may help identify promising therapeutic targets for HCC.

Epithelial-mesenchymal transition (EMT) plays an important role in cancer progression. During the EMT process, epithelial cancer cells lose their epithelial properties, such as cell polarity and intercellular adhesion, and gain mesenchymal properties, such as migration and invasion ability. Importantly, EMT has been associated with drug resistance of targeted therapies [3, 4]. EMT is important for HCC metastasis and has been closely associated with patient survival. Previous studies have suggested that sorafenib resistance may be due to the EMT process [5]. The development of sorafenib resistance in Huh7 cells may involve the PI3K/Akt signaling pathway. The PI3K/Akt signaling pathway works in parallel with the Raf/Ras/MAPK signaling pathway and is targeted by sorafenib [6]. EMT is coordinated by multiple EMT-induced transcription factors (EMT-TFs). These transcription factors have been shown to be involved in stemness, immune escape, and drug resistance [7], such as ZEB1/2, SNAI1/2, and TWIST1/2 [8].

Circular RNAs (CircRNA) are endogenous, abundant, and stable novel non-coding RNAs (ncRNAs) that are present in a variety of cell types. They have been closely associated with several diseases and cancers [9, 10]. Studies have demonstrated the unique biogenetic mechanisms and functions of circRNAs. Compared to circular microRNA (miRNA) in the cytoplasm which acts as sponges [11], nuclear-localized circRNAs act as transcriptional activators [12], circRNAs act as natural miRNA sponges by competitively binding with miRNA response elements to inhibit their function. circ-CSPP1 has been shown to reduce the inhibitory effect of miR-1236-3p on ZEB1 to promote EMT and ovarian cancer development. circ-CSPP1 accomplishes this by acting as a miR-1236-3p sponge [13]. hsa_circ_0020397 has been shown to regulate cell viability and invasion of colorectal cancer (CRC) cells by sponging miR-138 to promote TERT and PD-L1 expression [14]. Numerous studies have indicated that circRNAs are differentially expressed in HCC and play a key role in several biological processes of HCC. This suggests that circRNAs may be valuable diagnostic markers and/or therapeutic targets for HCC [15–19]. A previous study demonstrated that HCC patients with higher expression levels of hsa_circ_0003288 were associated with poor prognosis [20]. In this study, we investigated the role and mechanism of hsa_circ_0003288 on EMT, migration, and invasion of HCC, as well as the association between hsa_circ_0003288 and PD-L1 in HCC. Our results demonstrated that higher expression of hsa_circ_0003288 induced PD-L1 expression by acting as a sponge for miR-145. Furthermore, hsa_circ_0003288 promoted EMT, migration, and invasion by regulating PD-L1 in HCC. These findings provide strong evidence that hsa_circ_0003288 may be a valuable therapeutic target for the treatment of HCC.

**Materials and methods**

**Cell culture**

Human HCC cell lines, HepG2, Huh7, SMMC-7721, and Bel-7402 and human normal hepatic cell line, L02, were purchased from the cell bank of the Chinese Academy of Sciences. Cells were cultured in DMEM (high glucose) medium (Gibco BRL, Grand Island, NY) with 100 U/mL penicillin, 100 μg/mL streptomycin, and 10% heat-inactivated FBS (fetal bovine serum) (Invitrogen, Carlsbad, CA, USA) in a cell culture incubator with 5% CO2 at 37°C.

**Tissue samples**

Forty matched HCC and adjacent non-tumor liver tissues were obtained from the First Affiliated Hospital of Soochow University after informed consent from patients and Ethics Committee approval was obtained. Of the 40 patients, 18 patients were females and 22 were males. The average age was 58.26 years old. HCC tissues were evaluated by pathological examination. HCC patients did not undergo chemotherapy or radiotherapy prior to tissue sampling. Tissue samples were snap-frozen in liquid nitrogen until required.

**Western blot assays**

Total proteins were extracted from tissue samples using RIPA buffer (Cell Signaling Technology) supplemented with protease inhibitors (Sigma Aldrich, St. Louis, MO, USA). Total proteins were then separated on a 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to a nitrocellulose membrane (Millipore, Bedford, MA, USA). The membranes were blocked using 5% BSA in TBST buffer and incubated with the following primary antibodies: mouse anti-E-cadherin (610181A) and anti-N-cadherin (610,920, BD Biosciences, San Jose, CA, USA), rabbit anti-PD-L1 (13684S), anti-AKT (9272S), and anti–p-AKT (4060S) (Cell Signaling Technology, Houston, TX, USA), mouse anti-β-actin (sc-47778) and anti-mouse (sc-2005). Membranes were then washed and incubated with the appropriate secondary antibody conjugated with HRP: anti-mouse (sc-2005) and anti–rabbit (sc-2357, Santa Cruz Biotechnology). Specific protein bands were visualized using the ECL reagent (GE Healthcare Life Sciences, Piscataway, NJ, USA). Protein expression levels were normalized against β-actin levels. All experiments were performed in triplicate.
Real-time quantitative reverse transcriptase PCR (qRT-PCR)
Total RNA was isolated from tissue samples and cells using the HP Total RNA Kit (Omega Bio-tek, Stamford, CT, USA) based on the manufacturer’s instructions. Quantitation of total RNA was performed using the NanoDrop (Thermo Fisher Scientific, Waltham, MA, USA). cDNA was synthesized from total RNA using the M-MLV First Strand kit (Life Technologies, Gaithersburg, MD, USA). Platinum®SYBR®Green qPCR supermix-UDG with ROX (Invitrogen) was used for PCR amplification and was performed on the ABI PRISM 7500 Sequence Detection System (Applied Biosystems). PCR primer sequences are listed below: circ_0003288-F: 5′-TGCATC TTTCCTCAACATGTCTCT, circ_0003288-R: 5′-ATGC TGTCGACAAGAACCCTTTCAGA, miR-145-F: GAACATGTCTCGTATCTCTC, miR-145-R: CTAATTGTCTATGGGAGA, PD-L1-F: 5′-GCTGCA GGTGTCTGTTGTAGTGGCACC, β-actin-F: 5′-GGCGGCACCACCAGTACCT, β-actin-R: 5′-AGGAGCCGGA C TCTCATAC. 
PCR cycling conditions were as follows: 50 °C for 2 min, 95 °C for 10 min, followed by 40 cycles consisting of 95 °C for 15 s and 60 °C for 1 min. U6 expression levels were used to normalize miRNA expression levels. β-actin was used as the endogenous control for mRNA and circRNA expression levels. Relative RNA expression was calculated based on the 2−ΔΔCt method.

Luciferase reporter assays
PD-L1 3′-UTR and hsa_circ_0003288 sequences containing the miR-145 binding sites were cloned into the psiCHECK2 dual-luciferase vector (Promega, Madison, WI, USA). DNA fragments of PD-L1-3′-UTR, PD-L1-3′-UTR-mutant, hsa_circ_0003288, and hsa_circ_0003288-mutant were directly synthesized (GENEWIZ Inc., Suzhou, China), and then subcloned into the psiCHECK-2 vector. Afterward, the constructs were co-transfected with miR-145 mimics or the corresponding negative controls (miR-NC) into HepG2 and Huh-7 cells. Transient transfections of the miR-145 inhibitor and its corresponding negative control (anti-miR-NC) were performed using Lipofectamine 2000 (Invitrogen, Carlsbad, California, USA). After 48 h post-transfection, cells were harvested and luciferase activity was measured using the Dual-Luciferase Reporter Assay Kit (Promega). Data were presented as relative Renilla luciferase activity normalized against firefly luciferase activity.

RNA pull-down assay
A biotin-labeled hsa_circ_0003288 probe was synthesized directly by RiboBio Co., Ltd. The probe sequence was Bio-5′-AAGAACCTTTTCAGTTGAAAG (Inc1102984, RiboBio, Guangzhou, China). Hsa_circ_0003288 was transected with Lipofectamine 2000 reagent (Invitrogen thermo, USA) into HepG2 cells. Then cells were harvested and lysed in lysis buffer. After centrifugation, 50 μL supernatant were drained as the input, and the remaining were incubated with streptavidin Dynabeads (M-280, Invitrogen) conjugated with biotin-labeled hsa_circ_0003288 probe overnight at 4 °C. Finally, the total RNA was isolated and miR-145 expression was analyzed by qRT-PCR assay.

Fluorescence in situ hybridization (FISH)
In situ hybridization was performed with a Fluorescent In Situ Hybridization (FISH) Kit (RiboBio, Guangzhou, China). Cells were washed with PBS buffer solution and fixed in 4% paraformaldehyde for 10 min. Then, the cells were infiltrated with PBS containing 0.5% Triton X-100 at 4 °C for 5 min, washed with PBS three times, each time for 5 min, and prehybridized at 37 °C for 30 min before hybridization. An anti-hsa_circ_0003288, anti-18S, or anti-U6 oligodeoxynucleotide probe was added into the hybridization solution at 37 °C darkness overnight. The cells were incubated with DAPI for 10 min. Hsa_circ_0003288-cy3 FISH probes were designed and synthesized directly by RiboBio Co., Ltd. Mouse 18S FISH probes and mouse U6 FISH probes were served as the cytoplasmic and nuclear controls, respectively. Images were captured by a Leica TCS SP8 confocal imaging system (Leica, Germany).

Generation of L02 cells overexpressing hsa_circ_0003288
L02 cell lines were generated to overexpress hsa_circ_0003288. Briefly, full-length hsa_circ_0003288 was subcloned into the pLCDH-ciR lentiviral expression vector (Geneseed Biotech) to establish the pLCDH-hsa_circ_0003288-copGFP(T2A)Puro construct. We used GENEWIZ Inc. to directly synthesize the subcloned sequence of the front circular frame (SA) and back circular frame (SD) of circRNA and full-length of hsa_circ_0003288. The constructs were transiently transfected into cells using Lipofectamine 2000. An empty vector served as the negative control.

hsa_circ_0003288 knockdown using RNAi
A short interfering RNA (siRNA) against hsa_circ_0003288 (si-hsa_circ_0003288: 5′-CUGAAAGGU UCUUGACACGCTTT-3′) was used to knockdown hsa_circ_0003288 expression and was synthesized by Geneharma, Shanghai, China. Scrambled siRNA (5′-GAC UUUCCUUUCUGACAGCCTT-3′) served as a negative control. HCC cells were transiently transfected with
100 pmol of siRNA using Lipofectamine 2000 reagent (Invitrogen).

**Transwell migration and invasion assays**

Invasion and migration assays were performed using transwell plates (353,097, BD Falcon, USA). 24-well transwell chambers with 8 mm pore polycarbonate filters were coated with or without Matrigel for invasion and migration assays, respectively. 5 × 10⁴ cells were cultured in DMEM media with 1% FBS and placed on the upper chamber. DMEM media supplemented with 10% FBS was added to the bottom chamber, which served as the chemoattractant. After 48 h, media was aspirated and cells that adhered to the upper surface of the membrane were gently removed using a cotton swab. Cells that had attached to the lower layer of the membrane were then stained using 1% crystal violet for 30 min at room temperature and then imaged using a light microscope. Results were obtained from three independent experiments.

**In vivo studies**

Female BALB/c nude mice (6–8 weeks) were divided into two groups, i.e., the stable hsa_circ_0003288 silencing group and the control group (5 mice per group). The right flank of mice was subcutaneously injected with 2 × 10⁵ HepG2 cells transfected with the control vector or si-hsa_circ_0101145. 7 days post-injection, tumors that formed were measured (volume = 1/2 × length × width²) using a vernier caliper every 5 days. After 1 month, mice were euthanized by cervical dislocation, and tumors were excised and used for protein extraction and western blot analysis. All animal experiments were approved by the Ethics Committee of the First Affiliated Hospital of Soochow University.

**Statistical analysis**

Differences between the two groups were determined using paired or unpaired t-test (two-tailed). Association between the two groups was determined using Pearson’s correlation test. Results were presented as mean ± SEM and P < 0.05 was considered significant. Statistical analyses were performed using GraphPad Prism 5.02 software (GraphPad, San Diego, CA, USA).

**Results**

**Hsa_circ_0003288 promotes EMT, migration, and invasion of HCC**

Previous studies have demonstrated that HCC patients with higher expression of hsa_circ_0003288 have a poor prognosis [20]. EMT has been shown to be a key driver of tumor cell invasion and metastasis [21]. To investigate the biologic function of hsa_circ_0003288 in regulating EMT, we first measured hsa_circ_0003288 expression in HCC cell lines by qRT-PCR. Our results demonstrated that hsa_circ_0003288 expression was higher in HCC cell lines compared to normal L02 cells (Fig. 1a). Next, we overexpressed hsa_circ_0003288 in L02 cells (Fig. 1b). Western blot analysis showed that overexpression of hsa_circ_0003288 reduced the epithelial marker E-cadherin expression levels but increased mesenchymal marker N-cadherin expression levels (Fig. 1c). In addition, transwell assays demonstrated that overexpression of hsa_circ_0003288 promoted cell migration and invasion in L02 cells (Fig. 1d). Taken together, these results suggested that hsa_circ_0003288 may be associated with EMT in HCC cells.

**Hsa_circ_0003288 binds directly to miR-145 in HCC cells**

Endogenous circRNAs have been shown to function as miRNA sponges in various cancers [22]. We investigated the molecular mechanism by which hsa_circ_0003288 mediates EMT in HCC cells. Bioinformatic analysis was used to predict candidate miRNAs, which showed that hsa_circ_0003288 could interact with several miRNAs, such as miR-1179, miR-1200, miR-1233, miR-136, miR-145, miR-1203, and miR-942. To determine whether hsa_circ_0003288 could directly bind to miR-145 in HCC cells, the hsa_circ_0003288 region containing putative miR-145 binding sites (wild type/mutant) (Fig. 2a) were subcloned into the psiCHECK-2 luciferase vector and then transiently co-transfected with miR-145 mimics into HepG2 and Huh7 cells. Our results demonstrated that the psiCHECK2 luciferase reporter construct with the hsa_circ_0003288 wild type had a lower luciferase activity in HepG2 cells. However, luciferase activity did not change significantly in cells transfected with the mutated binding sites (Fig. 2b). Similar results were obtained using Huh7 cells (Fig. 2c). We then transiently overexpressed hsa_circ_0003288 (Fig. 1b) in HepG2 and Huh7 cells. We found that the differences in miR-145 levels were not significant between cells overexpressing hsa_circ_0003288 and the control (Fig. 2d, e). RNA pull-down assays demonstrated that endogenous miR-145 was pulled down by biotinylated probe against hsa_circ_0003288 in HepG2 cells (Fig. 2f). The fluorescence in situ hybridization (FISH) experiments showed that hsa_circ_0003288 was mainly distributed in plasma, suggesting that hsa_circ_0003288 might play a post-transcriptional regulation role (Fig. 2g). Taken together, these suggested the binding of hsa_circ_0003288 with miR-145. Taken together, our
findings demonstrated that has_circ_0003288 could act as a sponge for miR-145 in HCC cells.

miR-145 represses PD-L1 expression by directly targeting the 3′-UTR of PD-L1 in HCC cells

Previous studies have shown that PD-L1 plays an important role in EMT transition in lung and head and neck squamous cell carcinomas [23, 24]. Bioinformatics analysis predicted several miRNAs that could potentially target the 3′-UTR of PD-L1 mRNA. These included miR-200a, miR-200c, miR-20a, miR-145, miR-17, miR-519d, and miR-93. miR-145 has been previously demonstrated to be involved in regulating the EMT process in several cancers [25, 26]. Hence, we selected miR-145 for further study. We subcloned PD-L1 mRNA 3′-UTR containing the miR-145 binding site (wild type/mutant) into psiCHECK-2 vector (Fig. 3a), and then transiently co-transfected the reporter construct with miR-145 into HepG2 and Huh7 cells. Our results demonstrated that miR-145 could reduce the luciferase activity of PD-L1 3′-UTR wild type but not the PD-L1 3′-UTR mutant. This was observed both in HepG2 and Huh7 cells (Fig. 3b, c). Furthermore, overexpression of miR-145 using miR-145 mimics decreased PD-L1 expression, while knockdown of miR-145 using miR-145 inhibitor mimics increased PD-L1 levels in HepG2 and Huh7 cells (Fig. 3d, e). Taken together, these findings suggest that miR-145 could suppress PD-L1 expression by directly targeting the 3′-UTR of PD-L1 in HCC cells.

Hsa_circ_0003288 increases PD-L1 expression by acting as a miR-145 sponge

To further investigate the role of has_circ_0003288, we investigated whether has_circ_0003288 could attenuate endogenous miR-145-mediated suppression of PD-L1. We overexpressed has_circ_0003288 in HepG2 and
Hsa_circ_0003288 bind directly to miR-145 in HCC cells. a Predicted target sequences in hsa_circ_0003288 binding to miR-145. b, c Wild type or mutated hsa_circ_0003288 transfected into HepG2 or Huh-7 cells with miR-145 or negative control (miR-NC). Relative luciferase activity was determined 48 h post-transfection. U6 was used as the internal control. d, e Endogenous miR-145 levels in HepG2 and Huh-7 cells after transient overexpression of hsa_circ_0003288. f Cell lysates from HepG2 cells were incubated with biotinylated probes against hsa_circ_0003288; miR-145 enrichment was determined by qRT-PCR after pull-down. Results revealed that miR-145 was abundantly pulled down by the hsa_circ_0003288 probe in HepG2 cells. g The subcellular distribution of hsa_circ_0003288 was visualized by RNA Fluorescent in situ hybridization (FISH) in HepG2 cells. 18S was the positive control for cytoplasm, and U6 was the positive control for the nucleus. Scale bar: 20 μm. *P < 0.05; **P < 0.01; ***P < 0.001.
Huh7 cells transfected with miR-145 mimics and measured PD-L1 levels. Our results demonstrated that overexpression of miR-145 could reduce PD-L1 expression levels, while overexpression of hsa_circ_0003288 could prevent inhibition of PD-L1 expression in HepG2 and Huh7 cells (Fig. 4a–d). These results demonstrate that hsa_circ_0003288 could reduce the inhibitory effects of miR-145 on PD-L1 expression by functioning as a miR-145 sponge in HCC cells.

**miR-145 inhibits EMT, migration, and invasion of HCC cells**

To determine whether miR-145 could regulate the EMT phenotype in HCC cells, we transfected miR-145 mimics or miR-145 inhibitors into HepG2 and Huh7 cells. HepG2 and Huh7 cells transfected with miR-145 mimics had higher expression levels of E-cadherin and lower expression of N-cadherin compared to cells transfected with miR-NC (Fig. 5a). In contrast, knockdown of miR-145 in HepG2 and Huh7 cells had lower expression levels of E-cadherin and higher expression levels of N-cadherin (Fig. 5b). Furthermore, overexpression of miR-145 reduced the migratory and invasive ability of HepG2 and Huh7 cells (Fig. 5c), while knockdown of miR-145 increased their migration and invasion ability (Fig. 5d). Taken together, these findings indicated that miR-145 could suppress EMT, migration, and invasion of HCC cells.
**Hsa_circ_0003288 knockdown inhibits PD-L1 expression and inhibits EMT, migration, and invasion of HCC cells via the PI3K/AKT signaling pathway**

We next investigated whether hsa_circ_0003288 could regulate EMT and invasion in HCC cells. After siRNA knockdown of Hsa_circ_0003288 in HepG2 and Huh7 cells, we observed a significant decrease in PD-L1 mRNA and protein levels (Fig. 6a–c). In addition, hsa_circ_0003288 knockdown increased E-cadherin levels and reduced N-cadherin levels compared to control cells.
Furthermore, hsa_circ_0003288 knockdown reduced the migratory and invasive ability of HepG2 and Huh7 cells (Fig. 6e). These results suggested that reducing hsa_circ_0003288 levels could decrease PD-L1 expression and inhibit EMT and invasion of HCC cells.

We then overexpressed PD-L1 (Fig. 6f, g) in si-hsa_circ_0003288 HCC cells to determine whether hsa_circ_0003288-induced metastatic phenotypes could be rescued. Western blot assays (Fig. 6g) demonstrated that PD-L1 overexpression led to the recovery of EMT in both HepG2 and Huh7 cells after hsa_circ_0003288 silencing. Furthermore, transwell assays demonstrated that PD-L1 overexpression could restore the migration and invasion ability of both HepG2 (Fig. 6h) and Huh7 (Fig. 6i) cells after hsa_circ_0003288 silencing.

We next investigated what downstream signaling pathway PD-L1 participates in to regulate the metastatic phenotype of HCC. The PI3K/Akt pathway has been shown to play an important role in promoting EMT in multiple cancers [4]. Hence, we focused on the PI3K/Akt signaling pathway. Western blot assays were performed to measure p-AKT levels, which is an indicator of the activation of the PI3K/Akt pathway. P-AKT levels were measured in si-hsa_circ_0003288, PD-L1/si-hsa_circ_0003288,
and in control HCC cells. We observed that p-AKT and PD-L1 levels were reduced in si-hsa_circ_0003288 HCC cells compared to control cells (Fig. 6g). Overexpression of PD-L1 was found to increase p-AKT levels in PD-L1/si-hsa_circ_0003288 HCC cells compared to si-hsa_circ_0003288 HCC cells (Fig. 6g).

**Hsa_circ_0003288 expression levels are positively correlated with PD-L1 expression in HCC tissues**

To investigate the relationship between hsa_circ_0003288 and PD-L1, we measured the levels of hsa_circ_0003288 and PD-L1 in 40 HCC and paired non-cancerous tissues using qRT-PCR. HCC tissues were found to have
significantly higher hsa_circ_0003288 and PD-L1 mRNA expression levels when compared to paired non-cancerous liver tissues (Fig. 7a, b). Furthermore, the ratio of hsa_circ_0003288 levels (T/N) was positively correlated with PD-L1 mRNA expression levels (T/N) in HCC tissues (Fig. 7e). Importantly, of the 36 HCC tissues with high hsa_circ_0003288 levels, 30 tumors (76.7%) showed higher PD-L1 mRNA levels (Fig. 7c, d). Collectively, these findings suggest that hsa_circ_0003288 plays a key role in regulating PD-L1 expression in HCC.

**Knockdown of hsa_circ_0003288 inhibits in vivo tumor growth and EMT**

We next investigated the role of hsa_circ_0003288 in EMT of HCC using mouse models. BALB/c nude mice were subcutaneously injected with HepG2 cells with either stable hsa_circ_0003288-knockdown or control vector. We observed that tumor size was lower in the hsa_circ_0003288-knockdown group compared to the control vector group (Fig. 7f). Western blot assays demonstrated that knockdown of hsa_circ_0101145 increased E-cadherin expression but reduced N-cadherin expression in tumor tissues of mice (Fig. 7g). Our in vivo studies demonstrated that knockdown of hsa_circ_0003288 reduced HCC EMT.

**Discussion**

Recent studies have shown that circRNAs are differentially expressed between HCC and normal liver tissues. They play key roles in numerous biological processes, suggesting that circRNAs may be valuable diagnostic or therapeutic targets for HCC [15–19]. However, the underlying mechanism of circRNAs in the development and progression of HCC is yet to be deciphered. In the present study, we demonstrated that hsa_circ_0003288 expression levels were increased in HCC and functioned as a ceRNA to promote EMT and invasion by regulating PD-L1 expression.

CircRNAs are abnormally expressed in several types of cancers, such as lung, liver, and colorectal carcinomas [25–27]. We found that PD-L1 mRNA levels were upregulated in HCC tissues. Our results were consistent with those published by Tao et al. Furthermore, we demonstrated that hsa_circ_0003288 expression levels were significantly increased in HCC cells and tissues and found that increased hsa_circ_0003288 levels were positively correlated with PD-L1 expression levels in HCC tissues. Although circRNA levels are usually expressed at low levels, they play an important role in tumorigenesis and metastasis and may function as oncogenes or tumor suppressors [29–31]. circRNA MTO1 has been shown to inhibit the progression of HCC [28], while circRNA cTFRC has been shown to promote bladder carcinoma progression by acting as a sponge for miR-107 [32]. A previous study demonstrated that HCC patients with high expression levels of hsa_circ_0003288 had poor prognosis [20]. Furthermore, numerous circRNAs have been shown to be regulated during the EMT process in human breast cancer [28]. This suggests that hsa_circ_0003288 maybe have an important role during EMT and invasion of HCC. We demonstrated that L02 cells that transiently overexpressed hsa_circ_0003288 had reduced expression levels of E-cadherin and higher N-cadherin expression levels compared to the control cells. Transwell assays also demonstrated that overexpression of hsa_circ_0003288 increased the migration and invasive ability of L02 cells.

The underlying mechanism of circRNAs in tumorigenesis and progression have not been fully elucidated. Numerous publications have demonstrated that circRNAs act as miRNA sponges and play a role in the circRNA-miRNA-mRNA axis [26, 29]. circHIPK3 has been reported to be a tumor-related molecule in HCC, and functions as a sponge for miR-124 to control AQP3 expression [17]. hsa_circ_0020397 has been shown to increase the expression of miR-138 targets, TERT and PD-L1, to regulate the growth of colorectal cancer cells [14], while hsa_circ_0008305 (circPTK2) has been shown to function as a sponge for miR-429/miR-200b-3p that directly targets the TIF1 3’-UTR region in non-small cell lung cancer [25]. In the present study, bioinformatics analysis indicated putative binding of hsa_circ_0003288 and miR-145. Dual-luciferase reporter assays confirmed that miR-145 was able to bind to hsa_circ_0003288. And we demonstrated that miR-145 was abundantly pulled down by the hsa_circ_0003288 probe in HepG2 cells. Furthermore, we showed that hsa_circ_0003288 is mainly distributed in the cytoplasm. Additionally, our results demonstrated that miR-145 levels were unchanged after HepG2 and Huh-7 cells were transiently transfected with pLCDH-circPTK2-copGFP(T2A)Puro lentiviral expression vector. This is in agreement with previous studies that suggested circRNAs play an important role in biological and pathological processes by acting as microRNA (miRNA) sponges but not affecting miRNA expression [30]. MiRNAs are small non-coding RNAs that regulate gene expression and are involved in a variety of human cancers. In addition, miRNAs have been demonstrated to be good biomarkers for a variety of cancers [35]. We found that PD-L1 expression levels were down-regulated after transient transfection with miR-145 mimics in HepG2 and Huh7 cells. Furthermore, knockdown of miR-145 by transient transfection with miR-145 inhibitor mimics increased PD-L1 expression levels. Dual-luciferase reporter assays further demonstrated that miR-145 inhibited PD-L1 expression by binding to its 3’-UTR
region. The inhibition of PD-L1 expression by miR-145 could be rescued by overexpressing hsa_circ_0003288 in HepG2 and Huh7 cells.

Different molecular mechanisms are involved in the occurrence and development of EMT in human cancer. These include the regulation of non-coding RNAs, EMT transcription factors (EMT-TFs), alternative splicing factors, epigenetic modification, and post-translational regulation [31, 32]. LncRNA PTAR has been shown to regulate ZEB1 expression by competitive binding of miR-101-3p to promote EMT, invasion, and metastasis in ovarian cancers [33]. In this study, miR-145 was found to reduce HCC invasion by inhibiting EMT. Our findings are inconsistent with previous studies where miR-145 was found to promote EMT by regulating Fibroblast Growth Factor 10 (FGF10) [34]. However, our findings were consistent with the results published by Chen et al. where miR-145 was found to inhibit the invasion and metastasis of HCC cells [35]. This is not surprising since miRNAs play different roles depending on the cellular environment and specific targets or downstream effectors [25].

Higher expression levels of PD-L1 have been found in a variety of human cancers and has been closely associated with poor patient prognosis. Programmed death 1 (PD-1) and PD-L1 inhibitors have produced promising clinical results. Compared to paired non-cancerous liver tissues, we observed HCC tissues had significantly higher mRNA expression levels of PD-L1. Interestingly, the PD-L1 mRNA levels were positively correlated with hsa_circ_0003288 expression levels in HCC tissue samples. Previous studies have reported a strong correlation between PD-L1 expression and EMT status in a variety of human cancers [37]. Furthermore, studies have demonstrated that PD-L1 signaling plays an important role in maintaining the EMT status of renal cell carcinomas and breast cancer [38, 39]. We found that knockdown of hsa_circ_0003288 expression reduced PD-L1 mRNA and protein levels in HCC cells. Furthermore, knockdown of hsa_circ_0003288 increased E-cadherin expression levels and reduced N-cadherin levels compared to control cells. Most importantly, knockdown of hsa_circ_0003288 significantly reduced the migration and invasion ability of HCC cells. EMT, migration, and invasion of HepG2 and Huh7 cells were restored after overexpression of PD-L1 following hsa_circ_0003288 silencing. Using in vivo mouse models, we observed that knocking down hsa_circ_0003288 expression in HCC reduced tumor growth and EMT. The PI3K/AKT signaling pathway has been shown to be closely associated with EMT and tumor progression [4]. We demonstrated that p-AKT levels were reduced in si-hsa_circ_0003288 HCC cells, while p-AKT levels increased after PD-L1 was overexpressed in si-hsa_circ_0003288 HCC cells. Taken together, our findings suggest that hsa_circ_0003288 knockdown could decrease PD-L1 expression and inhibit EMT and invasion via the PI3K/AKT signaling pathway in HCC cells.

**Conclusion**

In summary, we identified the oncogenic role of hsa_circ_0003288 and its mechanism by which it regulates EMT and invasion of HCC. We found that hsa_circ_0003288 expression levels were significantly increased and positively correlated with PD-L1 expression levels in HCC. hsa_circ_0003288 promoted EMT and invasion of HCC by acting as a miR-145 sponge and upregulating PD-L1 expression levels via the PI3K/AKT signaling pathway. This suggests its oncogenic role in HCC development. Targeting hsa_circ_0003288 may provide a therapeutic strategy for the treatment of HCC.

**Limitations of the study**

Due to the limited availability of tumor samples, only PD-L1 mRNA and not protein expression levels were measured. Additional studies using a larger number of patient samples are required to validate our findings.

**Abbreviations**

EMT: Epithelial-mesenchymal transition; circRNAs: Circular RNAs; HCC: Hepato-cellular carcinoma; PD-L1: Programmed death-1 ligand 1; qRT-PCR: Real-time quantitative reverse transcriptase PCR; UTR: Untranslated region; EMT-TFs: EMT-induced transcription factors; ncRNAs: Non-coding RNAs; miRNA: Micro-RNA; CRC: Colorectal cancer; SDS-PAGE: Sodium dodecyl sulfate–polyacrylamide electrophoresis; siRNA: Short interfering RNA; FGF10: Fibroblast Growth Factor 10; PD-1: Programmed death 1.

**Acknowledgements**

We would like to thank the patients who consented to the use of their tumor samples for this study. Additionally, we would like to thank the Jiangsu Institute of Clinical Immunology of The First Affiliated Hospital of Soochow University for technical assistance.

**Authors’ contributions**

GLX wrote the main manuscript. GLX, PZ, JS, WSW and YHX performed the experiments. GLX, CFN, XGZ and XLZ designed the study. GLX, PZ, HSL and MML analyzed the data. All authors read and approved the final manuscript.

**Funding**

This study was supported by Natural Science Foundation of China [No. 81771945].

**Availability of data and materials**

The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

The present study was approved by the Ethics Review Committee of the First Affiliated Hospital of Soochow University. Written informed consent was obtained from the participating patients.
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

2. Yan L, Xu F, Dai CL. Relationship between epithelial-to-mesenchymal transition and the inflammatory microenvironment of hepatocellular carcinoma. J Exp Clin Cancer Res. 2018;37(1):203.

3. Poljak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265–73.

4. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29(34):4741–51.

5. van Malenstein H, Dekervel J, Verslype C, Van Cutsem E, Windmolders P, Nevens F, van Pelt J. Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. Cancer Lett. 2013;329(1):74–83.

6. Chen KF, Chen HL, Tai WT, Feng WC, Hsu CH, Chen PJ, Cheng AL. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther. 2011;337(1):155–61.

7. Puisieux A, Brabletz T, Carmel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol. 2014;16(6):488–94.

8. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour invasion and metastasis: yes, no, maybe? Curr Opin Cell Biol. 2016;43:7–13.

9. Rong D, Tang W, Li Z, Zhou J, Shi J, Wang H, Cao H. Novel insights into circular RNAs in clinical application of carcinomas. Onco Targets Ther. 2017;10:2183–8.

10. Yao R, Zou H, Liao W. Prospect of circular RNA in hepatocellular carcinoma: a novel potential biomarker and therapeutic target. Front Oncol. 2018;8:332.

11. Zheng Q, Bao C, Guo W, Li S, Chen J, Chen B, Luo Y, Lyu D, Li Y, Shi G, et al. Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nat Commun. 2016;7:11215.

12. Yang Q, Du WW, Wu N, Yang W, Awan FM, Fang L, Ma J, Li X, Zeng Y, Zang Z, et al. A circular RNA promotes tumorigenesis by inducing c-myc nuclear translocation. Cell Death Differ. 2017;24(9):1609–20.

13. Li QH, Liu Y, Chen S, Zong ZH, Du YP, Sheng XJ, Zhao Y. circ-C59P1 promotes proliferation, invasion and migration of ovarian cancer cells by acting as a miR-1236–3p sponge. Biomedicine & pharmacotherapy = Biomedicine & pharmacotherapie 2019;114:108832.

14. Zhang XL, Xu LL, Wang F. Hsa_circ_0002397 regulates colorectal cancer cell viability, apoptosis and invasion by promoting the expression of the miR-138 targets TERT and PD-L1. Cell Biol Int. 2017;41(9):1056–64.

15. Yao Z, Luo J, Hu K, Lin J, Huang H, Wang Q, Zhang P, Xiong Z, He C, Huang Z, et al. ZKSCAN1 gene and its related circular RNA (circZKSCAN1) both inhibit hepatocellular carcinoma cell growth, migration and invasion but through different signaling pathways. Mol Oncol. 2017;11(4):422–37.

16. Fu L, Chen Q, Yao T, Li T, Ying S, Hu Y, Guo J. Hsa_circ_0005986 inhibits carcinogenicity by acting as a miR-129-5p sponge and is used as a novel biomarker for hepatocellular carcinoma. Oncotarget. 2017;8(27):43878–88.

17. Chen G, Shi Y, Liu M, Sun J. circHIPK3 regulates cell proliferation and migration by sponging miR-124 and regulating AQP3 expression in hepatocellular carcinoma. Cell Death Dis. 2018;9(2):175.

18. Qin M, Liu G, Huo X, Tao X, Sun X, Ge Z, Yang J, Fan J, Liu L, Qin W. Hsa_circ_0001649: A circular RNA and potential novel biomarker for hepatocellular carcinoma. Cancer Biomarkers Section A Disease Markers. 2016;16(1):161–9.

19. Wang X, Li G, Liu H, Li T, Liu J, Zhao Q, Wang C. Comprehensive circular RNA profiling reveals that hsa_circ_0005075, a new circular RNA biomarker, is involved in hepatocellular carcinoma development. Medicine. 2016;95(22):e3811.

20. Yang G, Wang X, Liu B, Lu Z, Xu X, Xiu F, Liu Z, Li J. circ-BIRC6, a circular RNA, promotes hepatocellular carcinoma progression by targeting the miR-3918/Bcl2 axis. Cell Cycle. 2019;18(9):976–89.

21. Jiang Y, Zhan H. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion. Cancer Lett. 2020;468:72–81.

22. Cortes-Lopez M, Miura F. Emerging Functions of Circular RNAs. Yale J Biol Med. 2016;89(4):527–37.

23. Kim S, Koh J, Kim MY, Kwon D, Go H, Kim YA, Jeon YK, Chung DH. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenoscarcinoma of the lung. Hum Pathol. 2016;58:7–14.

24. Ock CY, Kim S, Keam B, Kim M, Kim TM, Kim JH, Jeon YK, Lee JS, Kwon SK, Hah JH, et al. PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget. 2016;7(13):15901–14.

25. Wang L, Tong X, Zhou Z, Wang S, Lei Z, Zhang T, Liu Z, Zeng Y, Li C, Zhao J. Circular RNA hsa_circ_0008305 (circPTK2) inhibits TGF-beta-induced epithelial-mesenchymal transition and metastasis by controlling TFGamma in non-small cell lung cancer. Mol Cancer. 2018;17(11):40.

26. Han D, Li J, Wang H, Xu X, Hou J, Gu Y, Qian C, Lin Y, Liu X, Huang M, et al. Circular RNA circMT01 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression. Hepatology. 2017;66(4):1151–64.

27. Hsiao KY, Lin YC, Gupta SK, Chang N, Yen L, Sun HS, Tai SJ. Noncoding Effects of Circular RNA CCDC66 Promote Colon Cancer Growth and Metastasis. Can Res. 2017;77(29):2339–50.

28. Conn SJ, Pillman KA, Toubia J, Conn VM, Salamandis M, Phillips CA, Roslan S, Sheibeier AW, Gregory PA, Goodall GJ. The RNA binding protein quaking regulates formation of circRNAs. Cell. 2015;160(6):1125–34.

29. Li Q, Pan X, Zhu D, Deng Z, Jiang R, Wang X. Circular RNA MATZB promotes glycolysis and malignancy of hepatocellular carcinoma through the miR-338-3p/PKM2 Axis under hypoxic stress. Hepatology. 2019;70(4):1298–316.

30. Kulcheski FR, Christoff P, Margis R. Circular RNAs are miRNA sponges and can be used as a new class of biomarker. J Biotechnol. 2016;238:42–51.

31. Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT: 2016. Cell. 2016;166(1):21–45.

32. Siegel RL, Miller KD, Jemal A. Cancer statistics 2016. CA Cancer J Clin. 2016;66(1):7–30.

33. Ackermann T, Gevaert K, de Ruiter D, Verbeek M, Vooijs M, van de Vijver M, et al. Circular RNAs in clinical application of carcinomas. Onco Targets Ther. 2018;11:16343–56.

34. Zhou Q, Zhang Y, Chen Y, Qian J, Zhang X, Yu K. A novel mTORC1/2 inhibitor (MTI-31) inhibits tumor growth, epithelial-mesenchymal transition in peritoneal dialysis-associated fibrosis by suppressing fibroblast growth factor receptor 10. J Biol Chem. 2019;294(41):15562–77.

35. Li C, Lu L, Feng R, Zhang K, Han S, Hou D, Chen L, Chu X, Wang R. The lnccRNA-RO/ miR-145 axis promotes invasion and metastasis in hepatocellular carcinoma via induction of epithelial-mesenchymal transition by targeting ZEB2. Sci Rep. 2017;7(1):4637.

36. Fomer A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–55.

37. Wang Y, Wang H, Zhan Q, Yang L, et al. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression. Mol Oncol. 2018;12(1):119.

38. Wang Y, Wang H, Zhan Q, Yang L, et al. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression. Mol Oncol. 2018;12(1):119.

39. Alsuliman A, Colak D, Al-Harazi O, Fitwi H, Tulbah A, Al-Tweigeri T, Al-Awlan M, Ghebeh H. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol Cancer. 2015;14:149.